Affimed wishes to focus its in-house programs on the clinical development of the products for Non-Hodgkin's Lymphoma and Hodgkin's Disease (AFM11, AFM12 and AFM13). In order to accommodate this focus, Affimed is actively seeking licensing or co-development partners for both AFM14 and AFM15 as well as the discovery programs for Leukaemia, Myeloma, solid tumors, metastasis and Non-Hodgkin's Lymphoma as well as non-cancer indications such as Autoimmune Disease, Allergy and Asthma. Depending upon the stage of development and the capabilities of the partner this can take the form of a license or a research collaboration with options for licensing.
If you would be interested in hearing more about any of these products or programs, please complete the form below and submit. Fields marked with an asterisk (*) are required.
Alternatively, you can contact us directly at the following address:
Dr. Volker Lang
CBO
Affimed Therapeutics AG
Im Neuenheimer Feld 582
D-69120
Heidelberg
v.lang@affimed.com
Tel.: +49 6221 65 307 0